ReviewTranslational andrology and urology2021
Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review.
Review in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic and clinical pathological significance of the systemic immune-inflammation index in urothelial carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Multi-omics study on tumor-associated macrophages remodeling the tumor microenvironment via the CXCL5-CXCR2 axis to drive immune escape in bladder cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.ESMO real world data and digital oncology · 2025Article
- Lymphadenectomy in upper tract urothelial carcinoma: Clinical insights and controversies (Review).Oncology reports · 2025Review
- Challenges in diagnosing and managing sarcomatoid urothelial carcinoma of the renal pelvis: a case report.Frontiers in oncology · 2025Article
- Occult urothelial carcinoma with mediastinal metastasis: A case report.Oncology letters · 2024Article
- TGFB1I1 promotes cell proliferation and migration in urothelial carcinoma.The Kaohsiung journal of medical sciences · 2024Article
- Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.International urology and nephrology · 2024Article
- Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy.Future oncology (London, England) · 2024Review
- Downregulation of the keratins CK13 and CK14 does not significantly affect cell viability of human urinary bladder carcinoma cells.Contemporary oncology (Poznan, Poland) · 2024Article
- Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.Current oncology reports · 2023Review
- Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.BMC cancer · 2023Article
- Atypical presentations of UTUC: a case report of three patients.Frontiers in oncology · 2023Article
- Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract.Current oncology (Toronto, Ont.) · 2022Article
- Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinomas (UC) arise from the urothelium that covers the proximal urethra, urinary bladder, and the upper urinary tract. In daily routine and clinical trials UC originating from different locations are often treated and investigated in the same manner. However, differences between the two locations seem to be apparent and may question in handling them as a single oncologic entity. In this review we discuss similarities and differences between bladder and upper urinary tract UC and consider their potential impact on treatment strategies. Despite similarities of UC in the bladder (BC) and the upper urinary tract (UTUC), clinicopathologic and molecular differences may question to generally assemble both as a single tumor entity. Treatment standards for UTUC are often adopted from BC. However, a specific investigation in the former may still be meaningful as shown by the example of adjuvant cisplatin based chemotherapy. In conclusion, future investigations should prioritize the understanding of the tumor biology of both BC and UTUC. This may reveal which UTUC can be treated according to treatment standards of BC and in which cases, a separate approach may be more appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.